# Cytokinetics Current Liabilities vs Total Assets Analysis

CYTK | Stock | ## USD 50.66 0.15 0.30% |

Cytokinetics financial indicator trend analysis is way more than just evaluating Cytokinetics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytokinetics is a good investment. Please check the relationship between Cytokinetics Current Liabilities and its Total Assets accounts. Continue to Trending Equities.

## Current Liabilities vs Total Assets

## Current Liabilities vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytokinetics Current Liabilities account and Total Assets. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cytokinetics' Current Liabilities and Total Assets is

**0.91**. Overlapping area represents the amount of variation of Current Liabilities that can explain the historical movement of Total Assets in the same time period over historical financial statements of Cytokinetics, assuming nothing else is changed. The correlation between historical values of Cytokinetics' Current Liabilities and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Liabilities of Cytokinetics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Current Liabilities i.e., Cytokinetics' Current Liabilities and Total Assets go up and down completely randomly.## Correlation Coefficient | 0.91 |

Relationship Direction | Positive |

Relationship Strength | Very Strong |

## Current Liabilities

The current portion of Total Liabilities; reported if the company operates a classified balance sheet that segments current and non-current liabilities.## Total Assets

Total assets refers to the total amount of Cytokinetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cytokinetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; [Intangibles]; Property Plant and Equipment Net; [TaxAssets] and Trade and Non Trade Receivables.Most indicators from Cytokinetics fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million. The current Issuance Purchase of Equity Shares is estimated to increase to about 345.2

**M**, while Enterprise Value over EBITDA is projected to decrease to (20.81) . 2019 | 2020 | 2021 | 2022 (projected) | |

Revenues USD | 26.87 M | 55.83 M | 70.43 M | 59.29 M |

Revenues | 26.87 M | 55.83 M | 70.43 M | 59.29 M |

## Cytokinetics fundamental ratios Correlations

**Click cells**to compare fundamentals

## Cytokinetics Account Relationship Matchups

## Cytokinetics fundamental ratios Accounts

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Accounts Payable | 5.25 M | 3.76 M | 8.16 M | 8.05 M | 21.09 M | 22.75 M | |

Accumulated Other Comprehensive Income | 137 K | 343 K | 500 K | 679 K | (869 K) | (891.87 K) | |

Total Assets | 294.81 M | 211.18 M | 289.81 M | 533.8 M | 841.32 M | 907.74 M | |

Current Assets | 274.3 M | 207.67 M | 233.75 M | 474.22 M | 535.67 M | 577.96 M | |

Assets Non Current | 20.52 M | 3.5 M | 56.06 M | 59.58 M | 305.65 M | 329.78 M | |

Cash and Equivalents | 125.21 M | 42.26 M | 36.43 M | 82.98 M | 112.67 M | 91.18 M | |

Cash and Equivalents USD | 125.21 M | 42.26 M | 36.43 M | 82.98 M | 112.67 M | 91.18 M | |

Total Debt | 31.78 M | 43.18 M | 136.07 M | 138.94 M | 269.93 M | 291.24 M | |

Debt Non Current | 31.78 M | 40.58 M | 131.45 M | 136.15 M | 255.07 M | 275.2 M | |

Total Debt USD | 31.78 M | 43.18 M | 136.07 M | 138.94 M | 269.93 M | 291.24 M | |

Deferred Revenue | 20.86 M | 23.06 M | 24.57 M | 87 M | 100.05 M | 107.95 M | |

Shareholders Equity | 109.84 M | 25.93 M | (10.94 M) | 113.38 M | 243.86 M | 263.12 M | |

Shareholders Equity USD | 109.84 M | 25.93 M | (10.94 M) | 113.38 M | 243.86 M | 263.12 M | |

Investments | 160.2 M | 156.47 M | 231.33 M | 418.03 M | 511.02 M | 551.37 M | |

Investments Current | 143.69 M | 156.47 M | 188.68 M | 381.07 M | 358.97 M | 387.31 M | |

Investments Non Current | 7.67 M | 16.52 M | 42.65 M | 36.95 M | 152.05 M | 164.05 M | |

Total Liabilities | 184.97 M | 185.24 M | 300.75 M | 420.42 M | 597.46 M | 644.62 M | |

Current Liabilities | 32.44 M | 22.19 M | 26.02 M | 31.2 M | 71.86 M | 77.53 M | |

Liabilities Non Current | 152.52 M | 163.05 M | 274.73 M | 389.22 M | 525.6 M | 567.09 M | |

Trade and Non Trade Payables | 5.25 M | 3.76 M | 8.16 M | 8.05 M | 21.09 M | 22.75 M | |

Property Plant and Equipment Net | 3.57 M | 3.5 M | 13.41 M | 16.27 M | 146.41 M | 157.97 M | |

Trade and Non Trade Receivables | 1.11 M | 2.23 M | 5.16 M | 4.42 M | 51.82 M | 55.91 M | |

Accumulated Retained Earnings Deficit | (646.08 M) | (743.32 M) | (865.02 M) | (992.31 M) | (1.21 B) | (1.24 B) |

## Cytokinetics Investors Sentiment

The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Investor biases related to Cytokinetics' public news can be used to forecast risks associated with investment in Cytokinetics. The trend in average sentiment can be used to explain how an investor holding Cytokinetics can time the market purely based on public headlines and social activities around Cytokinetics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.

Cytokinetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Cytokinetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Cytokinetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Cytokinetics.

## Cytokinetics Implied Volatility | 236.27 |

Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.

## Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.### Moving against Cytokinetics

0.66 | KZIA | Kazia Therapeutics | Fiscal Year End 6th of October 2022 | PairCorr |

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.

The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Directory module to find actively traded corporate debentures issued by US companies.

## Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.

Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum | Go | |

Money ManagersScreen money managers from public funds and ETFs managed around the world | Go | |

Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | Go | |

Technical AnalysisCheck basic technical indicators and analysis based on most latest market data | Go | |

Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | Go | |

Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | Go | |

Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | Go | |

Global CorrelationsFind global opportunities by holding instruments from different markets | Go | |

Focused OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences | Go | |

Bond DirectoryFind actively traded corporate debentures issued by US companies | Go | |

Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | Go | |

Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital | Go | |

Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets | Go |

Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 4.8 B | Quarterly Revenue Growth YOY 30.29 | Return On Assets -0.17 | Return On Equity -3.38 |

The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.